Nextleaf Evolves Glacial Gold, Building Trust with Wellness Consumers
Vancouver, British Columbia--(Newsfile Corp. - July 13, 2026) - Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) ("Nextleaf" or the "Company"), a multi-patented life science company and Canadian cannabis processor, is pleased to announce the evolution of Glacial Gold, the Company's flagship consumer cannabis brand. The most significant evolution in Glacial Gold's history, a milestone that reflects Nextleaf's continued development into a consumer-packaged goods ("CPG") comp
Biotechnology, Pharmaceuticals, Cannabis, Cannabis Extractor
2026-07-13 9:29 AM EDT | Nextleaf Solutions Ltd.
BioHarvest Sciences to Participate in the "Health, Wellness & Longevity" Virtual Conference Presented by Maxim Group LLC
British Columbia and Rehovot, Israel--(Newsfile Corp. - July 13, 2026) - BioHarvest Sciences Inc (NASDAQ: BHST) (FSE: 8MV0), a leader in Botanical Synthesis technology and sustainable plant-based molecule development, today announced that its Chief Executive Officer, Zaki Rakib, will participate in a fireside chat at the upcoming Maxim Health, Wellness & Longevity Conference, to be held virtually on July 22, 2026.
Biotechnology, Pharmaceuticals, Health
2026-07-13 8:00 AM EDT | BioHarvest Sciences Inc.
TempraMed Expands Institutional Healthcare Network with Meuhedet Health Services, a Leading HMO in Israel, Covering over 1 Million Lives
Highlights Meuhedet Health Services, Israel's third-largest Health Maintenance Organization (HMO), serving more than one million insured members, has accepted TempraMed's flagship VIVI Cap™ and VIVI Epi™ products. TempraMed products are now accepted by two of Israel's four national HMOs—Maccabi Healthcare Services and Meuhedet—providing institutional access to approximately four million insured
Technology, Biotechnology, Pharmaceuticals, Health
2026-07-09 7:00 AM EDT | TempraMed Technologies Ltd.
Telo Genomics Files Patent to Expand IP Portfolio to Liquid Biopsy MRD Applications for Multiple Myeloma
Toronto, Ontario--(Newsfile Corp. - July 9, 2026) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo"), a leader in diagnostic and prognostic innovation through advanced telomere analytics, today announced that it has filed a U.S. provisional patent application seeking to protect a new TeloView® biomarker algorithm for use with liquid biopsy samples, even those with minimal residual disease ("MRD") in the management of patients with multiple myeloma ("MM"). "
2026-07-09 7:00 AM EDT | Telo Genomics Corp.
Commercialization Application Filed by Hemostemix for the Treatment of Vascular Dementia, Angina and Pain
Calgary, Alberta--(Newsfile Corp. - July 8, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) ("Hemostemix" or the "Company"), the leading autologous (patient's own stem cells) regenerative medicine company is pleased to announce that it has filed its application under the Bahamas Longevity and Regenerative Therapies Act (LARTA) for a commercial Phase I Basket Clinical Trial evaluating VesCell™ in patients suffering from vascular dementia, refractory angina and pain.
Biotechnology, Pharmaceuticals, Health
2026-07-08 10:08 AM EDT | Hemostemix Inc.
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
New York and Rockville, Maryland--(Newsfile Corp. - July 8, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has accepted a new Meeting Request from the U.S. Food and Drug Administration (FDA)'s Center for Drug Evaluation and Research (CDER) to review the Company's pharmacodynamic response biomarker data (the "OST-HER2 Biomarker Data") –
2026-07-08 9:00 AM EDT | OS Therapies
Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform
Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® technology, today announced the opening of a new office at McMaster Innovation Park in Hamilton, Ontario, supporting the Company's expanding radiopharmaceutical research and business development a
Biotechnology, Pharmaceuticals, Health
2026-07-08 3:15 AM EDT | Defence Therapeutics Inc.
InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4
British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a who
Biotechnology, Pharmaceuticals
2026-07-06 6:20 PM EDT | InMed Pharmaceuticals
OS Therapies Third Quarter 2026 Corporate Outlook
New York and Rockville, Maryland--(Newsfile Corp. - July 6, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today provides a third quarter 2026 corporate outlook. The outlook focuses on upcoming clinical and regulatory milestones for the Company's lead program OST-HER2 in the prevention or delay of recurrence in fully resected, pulmonary metastatic osteosarcoma (the "Me
2026-07-06 9:00 AM EDT | OS Therapies
CBIH Announces Recognition Initiative Funded Through CEO's Personal Share Holdings
Houston, Texas--(Newsfile Corp. - July 6, 2026) - Cannabis Bioscience International Holdings, Inc. (OTCID: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announces that Dante Picazo, Chief Executive Officer of the Company, has designated 500,000,000 shares of common stock from his personal holdings to honor the directors, employees, and key associates whose dedication, loyalty, and work have helped shape CBIH's journey and strengthen the Company through years
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-07-06 7:00 AM EDT | Cannabis Bioscience International Holdings
TempraMed Signs LOI for Exclusive Distribution in Kuwait, Expanding Presence in High-Growth Gulf Region Healthcare Market
Highlights TempraMed signs non-binding LOI for exclusive distribution in Kuwait with Elegir Trading Kuwait represents a high-value market with significant demand for insulin, GLP-1 therapies, biologics, and other temperature-sensitive medications LOI includes minimum annual purchase commitments in Year 1 Expands TempraMed's footprint across the Middle East and supports broa
Technology, Biotechnology, Pharmaceuticals, Health
2026-07-06 7:00 AM EDT | TempraMed Technologies Ltd.
Trenchant Technologies Capital Corp. Announces Private Placement Offering of up to $1 Million Convertible Debentures
Vancouver, British Columbia--(Newsfile Corp. - July 3, 2026) - Trenchant Technologies Capital Corp. (CSE: AITT) (the "Company" or "Trenchant") is pleased to announce a private placement (the "Offering") of convertible debentures (each, a "Debenture") for gross proceeds of up to $1,000,000. The Offering consists of the issuance of convertible debentures of the Company (the "Debentures") bearing interest at a rate of 12% per annum and maturing one year f
Technology, Banking / Financial Services, Biotechnology, Healthcare and Hospitals
2026-07-03 4:00 PM EDT | Trenchant Technologies Capital Corp.
Modern Luxury Vegas Recognizes Dr. Christina Rahm Among Its 2026 Power Players
Las Vegas, Nevada--(Newsfile Corp. - July 2, 2026) - Dr. Christina Rahm, renowned scientist, entrepreneur, humanitarian and founder of DRC Ventures and ROOT Brands, was recognized as one of Modern Luxury Vegas' 2026 Power Players and joined fellow honorees at a celebration hosted by Modern Luxury Vegas on June 11. Held at Maroon, the invitation-only gathering brought together leaders featured in the publication's Power Players initiative, which highlights influential individuals shapin
Biotechnology, Food / Beverages, Health
2026-07-02 4:32 PM EDT | DRC Ventures
Izotropic Executes Formal Agreement with Izotropic Africa for Exclusive Distribution Throughout Africa and the GCC
British Columbia and Casablanca, Morocco--(Newsfile Corp. - July 2, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing IzoView, a dedicated breast CT imaging system for the more accurate screening and diagnosis of breast cancers, announces that, further to its
2026-07-02 8:00 AM EDT | Izotropic Corporation
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
New York and Rockville, Maryland--(Newsfile Corp. - July 2, 2026) - OS Therapies, Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), the world leader in gene-edited, Listeria-based cancer immunotherapies, today announced that it has appointed Dr. Craig Eagle to the Company's Board of Directors. Dr. Eagle currently serves as the Company's Chief Medical Advisor
2026-07-02 7:30 AM EDT | OS Therapies
Kiora Pharmaceuticals to Participate in Piper Sandler Virtual Ophthalmology Symposium
Encinitas, California--(Newsfile Corp. - July 2, 2026) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that it will participate in an investor fireside chat at the Piper Sandler Virtual Ophthalmology Symposium. Presentation Details Date: Thursday, July 9, 2026 Time: 2:30 p.m. Eastern Daylight Time Live Presentation: Available on Kiora's Investor Relations homepage at ir.ki
Biotechnology, Pharmaceuticals
2026-07-02 7:00 AM EDT | Kiora Pharmaceuticals, Inc.
Sharp Therapeutics Announces Filing of Amended and Restated Management Information Circular and New Annual Meeting Date
Pennsylvania and Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that its annual meeting of shareholders will be held at 10:00 a.m. (Toronto time) on July 21, 2026 (the "Meeting"), having been postponed from the initial meeting date of June 30, 2026. The Company has filed an amended and restated notice of meeting (the "Amended and Restated NOM") and an a
2026-06-30 5:00 PM EDT | Sharp Therapeutics Corp.
Theralase(R) Receives Receipt for C$100 Million Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - June 30, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has filed and obtained a receipt for a final base shelf prospectus dated June 29, 2026 ("P
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-06-30 4:30 PM EDT | Theralase Technologies Inc.
Envoy Medical Submits First Module of Modular Premarket Approval Application to the U.S. Food and Drug Administration for Breakthrough-Designated Device
White Bear Lake, Minnesota--(Newsfile Corp. - June 30, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced the submission of the first module of its Modular Premarket Approval ("PMA") application to the U.S. Food and Drug Administration ("FDA") for its FDA Breakthrough Device-designated product. The submissi
Biotechnology, Healthcare and Hospitals
2026-06-30 8:30 AM EDT | Envoy Medical, Inc.
OS Therapies Provides U.S. Regulatory Update
Type B Meeting requested to follow up on September 2025 End of Phase 2 FDA Meeting guidance on statistical methods to be used for BLA Submission Seeking to align FDA with MHRA & EMA on 3-year overall survival as approval endpoint Biomarker data submitted to FDA BEST program as surrogate clinical efficacy data Synthetic historical control arm OST-400 recruitment potentially adds comparator for BLA submission under the Accelerated Approva
2026-06-30 7:40 AM EDT | OS Therapies